The Week in Review #28
The approval of revolutionary products created by biotech firms with solid scientific fundamentals, superior scientists and advanced technologies is what motivates us to pick for investment biotech and biopharmaceutical firms. So, let’s see what has been approved in the parting week from firms that we picked for investment.
Prohost Picked Firm
Next Generation Sequencing
The China National Drug Administration (CNDA) granted Illumina approval for its MISeqDx - a next-generation sequencing system. Illumina can now market and sell the MiSeqDx . . .
This content is for paid subscribers.
Prohost Letters September 3, 2018